NOVELION THERAPEUTICS INC - COM NEW (NVLNF)

CUSIP: 67001K202

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Equity / COM NEW
Total 13F shares
13,418,874
Share change
-1,216,260
Total reported value
$39,720,698
Put/Call ratio
99%
Price per share
$2.96
Number of holders
43
Value change
-$3,661,731
Number of buys
9
Number of sells
21

Quarterly Holders Quick Answers

What is CUSIP 67001K202?
CUSIP 67001K202 identifies NVLNF - NOVELION THERAPEUTICS INC - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NOVELION THERAPEUTICS INC - COM NEW (NVLNF) as of Q3 2018

As of 30 Sep 2018, NOVELION THERAPEUTICS INC - COM NEW (NVLNF) was held by 43 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,418,874 shares. The largest 10 holders included EdgePoint Investment Group Inc., Broadfin Capital, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, MORGAN STANLEY, Sarissa Capital Management LP, Healthcare Value Capital, LLC, Prosight Management, LP, JW Asset Management, LLC, and Artal Group S.A.. This page lists 43 institutional shareholders reporting positions in this security for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.